Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01665794
• Other study ID #: 12-1088
• Secondary ID: NCI-2012-01168
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: August 13, 2012
• Est. completion date: November 1, 2024

Study information

• Verified date: April 2023
• Source: University of Chicago
• Contact: Cancer Clinical Trials Office
• Phone: 1-855-702-8222
• Email: cancerclinicaltrials[@]bsd.uchicago.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will investigate the effects of adding carfilzomib to the combination of pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with relapsed or refractory multiple myeloma. This portion of the study is complete.

This study will also investigate the effects of adding daratumumab to the combination of carfilzomib, pomalidomide and dexamethasone.

Description:

Patients receive carfilzomib, pomalidomide, and dexamethasone in 28 days treatment cycles. Study treatment continues for as long a their myeloma does not worsen and they do not have unacceptable side effects. After completion of study treatment, patients are followed for up to 2 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 101
• Est. completion date: November 1, 2024
• Est. primary completion date: November 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Relapsed and relapsed/refractory multiple myeloma requiring systemic therapy

• Failed at least one prior treatment for multiple myeloma (must have received lenalidomide)

• To be enrolled as second line therapy: Must be refractory to lenalidomide (progression on therapy or within 60 days of lenalidomide dosing)

• Measurable disease, as indicated by one or more of the following:

• Serum M-protein >= 0.5 g/dL

• Urine M-protein >= 200 mg/24 hours

• If serum protein electrophoresis is felt to be unreliable for routine M-protein measurement, then quantitative immunoglobulin levels are acceptable

• Involved serum free light chains = 10 mg/dL (free light change ratio must be abnormal)

• Aged 18 years or older

• Life expectancy of more than 3 months

• Eastern Cooperative Oncology Group (ECOG) performance status 0-2

• Adequate Liver Function

• Bilirubin < 1.5 times the upper limit of normal (ULN)

• Aspartate aminotransferase (AST) < 2.5 times ULN

• Alanine aminotransferase (ALT) < 2.5 times ULN

• Absolute neutrophil count (ANC) >= 1.0 x 10^9/L

• Hemoglobin >= 8 g/dL

• Platelet count >= 75 x 10^9/L (should be independent of platelet transfusions for at least 2 weeks)

• Calculated or measured creatinine clearance of >= 30 mL/minute

• Written informed consent

• Negative pregnancy test (for women of childbearing potential) within 10-14 days of starting study treatment and again within 24 hours of first pomalidomide dose

• Must agree to practice abstinence or use two acceptable methods of birth control

• Men must agree to use latex condom during sexual contact with women of childbearing potential (even if post vasectomy)

• Must agree to adhere to all study requirements, visit schedule, outpatient treatment, required concomitant medications, and laboratory monitoring

• Must register to mandatory POMALYST REMS™ program and be willing and able to comply with the requirements of the POMALYST REMS™ program

Exclusion Criteria:

• Patients for whom there is the prospect of stem cell transplantation in the next 6 months in the treatment plan are excluded

• POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)

• Plasma cell leukemia

• Waldenström's macroglobulinemia or immunoglobulin M (IgM) myeloma

• Radiotherapy to multiple sites or immunotherapy within 4 weeks before start of protocol treatment (localized radiotherapy to a single site at least 1 week before start is permissible)

• Participation in an investigational therapeutic study within 3 weeks or within 5 drug half lives (t1/2) prior to first dose, whichever time is greater

• Patients known to be refractory to any proteasome inhibitor other than bortezomib or carfilzomib

• Pregnant or lactating

• History of allergy to mannitol or prior hypersensitivity to thalidomide, lenalidomide or pomalidomide

• Major surgery within 3 weeks prior to first dose,

• Prior peripheral stem cell transplant within 12 weeks of study enrollment

• Has received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal (with the exception of hormones for thyroid conditions or estrogen replacement therapy [ERT]), or any investigational therapy within 21 days of enrollment

• Myocardial infarction within 6 months prior to enrollment, New York Heart Associate (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities

• Uncontrolled hypertension or diabetes

• Acute active infection requiring systemic antibiotics, antivirals, or anti fungals within two weeks prior to first dose

• Known or suspected human immunodeficiency (HIV) infection, known HIV seropositivity

• Active hepatitis A, B, or C infection

• Non-hematologic malignancy within the past 3 years except adequately treated basal cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix or breast, prostate cancer < Gleason grade 6 with stable prostate specific antigen levels or cancer considered cured by surgical resection alone

• Any clinically significant medical disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent

• Significant neuropathy (grades 3-4, or grade 2 with pain) at the time of the first dose and/or within 14 days before enrollment

• Contraindications to any of the required concomitant drugs, including proton-pump inhibitor (eg, lansoprazole), enteric-coated aspirin, allopurinol or if a history of prior thrombotic disease, warfarin or low molecular weight heparin

• Subjects in whom the required program of PO and IV fluid hydration is contraindicated, eg, due to pre-existing pulmonary, cardiac, or renal impairment

• Subjects with known or suspected amyloidosis of any organ

• Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis

• Prior exposure to daratumumab

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Pomalidomide
Pomalidomide taken orally at assigned dose.
• Carfilzomib
Carfilzomib given by intravenous (IV) infusion at assigned dose.
• dexamethasone
Dexamethasone taken orally of given by IV infusion.
• Daratumumab
Daratumumab given by intravenous (IV) infusion at assigned dose.

Locations

Country	Name	City	State
Canada	University Health Network - Princess Margaret Cancer Center	Toronto	Ontario
United States	University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan
United States	University of Chicago Comprehensive Cancer Center	Chicago	Illinois
United States	Wayne State University - Karmonos Cancer Center	Detroit	Michigan
United States	Sarah Cannon Research Institute	Nashville	Tennessee

Sponsors (3)

Lead Sponsor	Collaborator
University of Chicago	Multiple Myeloma Research Foundation, National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD) of carfilzomib when administered in combination with pomalidomide and dexamethasone		28 days
Primary	Partial response rate after 4 courses according to International Myeloma Working Group (IMWG) criteria	The proportion and exact 95% binomial confidence interval for the response rate will be reported adjusted for the two-stage design of this trial.	4 months
Primary	Response rates of carfilzomib, pomalidomide, dexamethasone, and daratumumab dosing according to International Myeloma Working Group (IMWG) criteria		4 months
Secondary	Overall response rate	Defined as at least a partial response to therapy, will be reported along with its exact 95% binomial confidence	Up to 2 years
Secondary	Time to progression	Estimated using the product-limit method of Kaplan and Meier.	Up to 2 years
Secondary	Duration of response	Assessed conditional upon achieving at least a partial response.	From the date of the clinical examination which confirmed the response, until the date of disease progression, or censoring at the date of last clinical follow-up up to 2 years
Secondary	Progression-free survival	Estimated using the product-limit method of Kaplan and Meier.	From the date of first therapy until the date of documented disease progression or death up to 2 years
Secondary	Overall survival	Estimated using the product-limit method of Kaplan and Meier.	Up to 2 years